Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic Study of CZN001 (renamed HZN-825)

Next Previous
Search
Trial Profile

A Pharmacokinetic Study of CZN001 (renamed HZN-825)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fipaxalparant (Primary)
  • Indications Diffuse scleroderma; Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Horizon Therapeutics plc

    • Most Recent Events

    • 12 Sep 2023 Results assessing Pharmacokinetics, Safety & Tolerability of HZN-825, a Lysophosphatidic Acid Receptor 1 Antagonist, Following Single & Multiple Doses in Healthy Japanese Subjects presented at the 2023 American College of Clinical Pharmacology Annual Meeting
    • 12 Sep 2023 Results (n=8) ssessing assess pharmacokinetics,metabolism, excretion and mass balance of HZN-825in humans after oral administration of 14C-HZN-825 presented at the 2023 American College of Clinical Pharmacology Annual Meeting
    • 24 Mar 2023 Results presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top